Literature DB >> 31189042

Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy.

Khashayar Esfahani1, Najwa Buhlaiga1, Paméla Thébault2, Réjean Lapointe2, Nathalie A Johnson3, Wilson H Miller3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31189042     DOI： 10.1056/NEJMc1903064

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  54 in total

Review 1.  [Novel cancer treatment and the cardiovascular risk : What should cardiologists know?]

Authors:  Matthias Totzeck; Tienush Rassaf
Journal:  Herz       Date:  2020-04       Impact factor: 1.443

2.  Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases.

Authors:  Ranjan Pathak; Anjan Katel; Erminia Massarelli; Victoria M Villaflor; Virginia Sun; Ravi Salgia
Journal:  Oncologist       Date:  2021-08-25

Review 3.  Moving towards personalized treatments of immune-related adverse events.

Authors:  Khashayar Esfahani; Arielle Elkrief; Cassandra Calabrese; Réjean Lapointe; Marie Hudson; Bertrand Routy; Wilson H Miller; Leonard Calabrese
Journal:  Nat Rev Clin Oncol       Date:  2020-04-03       Impact factor: 66.675

Review 4.  Targeted degradation of immune checkpoint proteins: emerging strategies for cancer immunotherapy.

Authors:  Jie Xu; Jean-Philippe Brosseau; Hubing Shi
Journal:  Oncogene       Date:  2020-10-06       Impact factor: 9.867

5.  Alemtuzumab and Fatal Myocarditis.

Authors:  Neil J Scolding; Hiam Ali; Mary Sheppard; Andre R Simon
Journal:  Neurol Clin Pract       Date:  2021-02

Review 6.  What the Cardiologist Needs to Know About Cancer Immunotherapies and Complications.

Authors:  Marina Frayberg; Anthony Yung; Leyre Zubiri; Daniel A Zlotoff; Kerry L Reynolds
Journal:  Curr Treat Options Oncol       Date:  2021-05-26

Review 7.  Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms.

Authors:  Javid Moslehi; Andrew H Lichtman; Arlene H Sharpe; Lorenzo Galluzzi; Richard N Kitsis
Journal:  J Clin Invest       Date:  2021-03-01       Impact factor: 14.808

Review 8.  Adverse events induced by immune checkpoint inhibitors.

Authors:  Ana Luisa Perdigoto; Harriet Kluger; Kevan C Herold
Journal:  Curr Opin Immunol       Date:  2021-02-25       Impact factor: 7.486

Review 9.  Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors.

Authors:  Alan H Baik; Katy K Tsai; David Y Oh; Mandar A Aras
Journal:  Clin Sci (Lond)       Date:  2021-03-12       Impact factor: 6.124

10.  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.

Authors:  Julie R Brahmer; Hamzah Abu-Sbeih; Paolo Antonio Ascierto; Jill Brufsky; Laura C Cappelli; Frank B Cortazar; David E Gerber; Lamya Hamad; Eric Hansen; Douglas B Johnson; Mario E Lacouture; Gregory A Masters; Jarushka Naidoo; Michele Nanni; Miguel-Angel Perales; Igor Puzanov; Bianca D Santomasso; Satish P Shanbhag; Rajeev Sharma; Dimitra Skondra; Jeffrey A Sosman; Michelle Turner; Marc S Ernstoff
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.